Gene Therapy in Rare Disease Research
A look at home and dosing site considerations.
Hope. The Power for the Rare Disease Journey
Editor-in-Chief Lisa Henderson speak about therapeutic needs, rare diseases in children, and the SCORR Marketing survey on innovative or flexible trial designs.
Clinical Design: A Deep Dive
Findings from a new ACT and SCORR Marketing survey reveal the most actively used flexible design approaches in clinical research-many with application in rare disease.
Clinical Trial Evolution: A CRO’s Perspective
Leader of one longtime CRO discusses the marked changes in clinical trial practice from past to present-and the company’s unique focus.
Patient Experience Moves to Center Stage in Medical Product Development
Jill Wechsler details the continued rise of incorporating the “patient experience” in drug development measures.
Models of Engagement: Patients as Partners in Clinical Research
Exploring three distinct patient partnership models to help researchers assess which methods of engagement could work best for their clinical programs.
Any Cancer Can Be a 'Rare Cancer'
With more common cancers now increasingly broken down by specific genomic defects, the future of research for any cancer is entirely, and unequivocally, molecular.
Monoclonal Antibodies: Clinical Pharmacology Keys
Outlining the unique pharmacokinetic factors that should be considered when designing and running early stage clinical trials for monoclonal antibodies.
The Need and Opportunity for a New Paradigm in Clinical Trial Execution
Sobering statistics collected on clinical trial execution point to the eventual convergence of healthcare and clinical research operating environments.
Policy and Practice Come Together on EU Vaccine Thrust
Peter O’Donnell explores the convergence of policy and science in new vaccine R&D pursuits in Europe.
Applied Clinical Trials, June 2018 Issue (PDF)
Click the title above to open the Applied Clinical Trials June 2018 issue in an interactive PDF format.
Enrollment Cycle Times Can and Should Be Optimized
Case study demonstrates that site activation is a key driver in determining patient enrollment cycle time.
